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Abstract
Sepsis kills nearly 1 million people each year in the United
States and sepsis-related hospitalizations cost approximately $24
billion annually (Paoli, Reynolds, Sinha, Gitlin, & Crouser,
2018). Current treatment guidelines are limited to targeted
antibiotics and hemodynamic support. While antibiotics are the
definitive treatment to eradicate the infectious pathogen, there
are currently no standard-of-care treatments that consistently and
successfully attenuate the damage sustained to the body by its
own inflammatory response to infection. Many different
treatments have been trialed and failed to show improved
outcomes. Vitamin C, or ascorbic acid, has long been associated
with supporting immune function, and has been studied in the
past in various related capacities. More recently, a study initiated
by Dr. Paul Marik has spurred much discussion and additional
research regarding the potential use of ascorbic acid as an
adjunctive treatment for sepsis patients. Research suggests that it
may reduce damage by reducing oxidative stress, regulate the
body’s immune response, and facilitating the production of
endogenous vasopressin. Discussion will include the mechanism
of action of ascorbic acid in the body, its potential role, efficacy,
and safety in the treatment of sepsis, as well as additional
treatment components. Also discussed is the cost in both dollars
and mortality, of waiting to implement the widespread use of
what appears in some studies to be a low-cost, low-risk, highreward treatment.

Introduction
Sepsis is an ongoing cause of morbidity and mortality in the
United States. It is the most common discharge diagnosis for adult
patients and the costliest major cause of inpatient admissions
(Esposito et al., 2018). The standard of care treatment involves
early identification of infection, fluid resuscitation, and broadspectrum intravenous (IV) antibiotics until cultures can assist with
narrowing to a specific pathogen (Rhodes et al., 2017).
Unfortunately, in the time that it can take to identify the source of
infection, many patients progress to septic shock, which carries a
mortality rate of up to 80% (Paoli et al., 2018). Sepsis is loosely
defined as a systemic infection that causes organ dysfunction due
to the body’s immune response. Part of the dysregulation of the
immune response involves inflammation, oxidative stress, and the
body’s subsequent response. Given its antioxidant properties, the
theoretical use of vitamin C supplementation in sepsis is not
necessarily new, but is being studied more intensely in recent
years, largely due to a promising 2016 retrospective study by Dr.
Paul E. Marik of Norfolk, Virginia.

Statement of the Problem
In the United States, nearly 1 million patients are
admitted each year for sepsis. Many sources suggest that
the incidence is increasing. One study reports an increase
of 8.7% per year over the course of 20-years. More than
half of all inpatient deaths are due to infection. In
addition to the lives lost, sepsis draws a large amount of
money and resources.

The average inpatient length of stay for a patient with sepsis is
75% longer than for other illnesses, requiring corresponding
supplies and staffing. In 2013, only 3.6% of hospital stays were
due to sepsis, but this population utilized 13% of the cost of
resources at approximately $24 billion. (Paoli, et al., 2018)
Oxidative stress on vasculature during acute sepsis can lead to
hemodynamic instability, increased inflammation, and death.
Patients who progress from sepsis to septic shock have mortality
rates of approximately 30-50% (Carr, Shaw, Fowler, & Natarajan,
2015). Aside from current antibiotics, there are no other mainstay
medications in treatment of sepsis.

Research Questions
• What is the role of ascorbic acid in the human body and what
theoretical mechanisms of action does it have in a patient with
sepsis?
• In patients with sepsis, has administration of intravenous
ascorbic acid been shown to decrease mortality rates when
compared to current standard of care?
• At what dose might there be increased benefit from ascorbic
acid supplementation, and is that dose beyond the standard
replacement from enteral or parenteral nutrition that is routinely
administered to critically ill patients?
• In treatment of sepsis, is intravenous ascorbic acid a cost
effective treatment when combined with the current regimen of
intravenous fluid resuscitation and antibiotic therapy? What are
the risks and benefits to delaying implementation of this
treatment option?

Literature Review
Mechanism of action
Vitamin C (ascorbic acid) has been proven to play many major
roles in the normal function of the human body. The antioxidant
properties of ascorbic acid help to prevent oxidative stress from
causing damage to cellular proteins. It also aids in the creation and
function of similarly-acting components. It helps to produce
catecholamines, cortisol, and vasopressin (Moscowitz et al., 2018).
It is a vital part of growth and repair of tissues due to its role in
collagen formation, which is utilized throughout the body in many
areas, including tendons, ligaments, and vasculature.

Safety and Efficacy
In a randomized, double-blind, placebo-controlled trial by Fowler
et al., 2014, no patients were removed from the study due to
adverse events after receiving low or high-dose IV ascorbic acid.
Marik (2017) has been credited with bringing this treatment into
the public eye most recently. His study evaluated outcomes of 94
patients being treated for sepsis. The primary outcome evaluated
was in-hospital survival. He used a combination of ascorbic acid,
thiamine, and hydrocortisone to treat 47 patients and then
retrospectively matched them to previous patients with similar
conditions who had been treated using only traditional standard of
care for sepsis. The results appear to be dramatic.

The treatment group saw only 4 fatalities, and no patients
developed progressive organ failure. Carr et al., (2017) found
that C-reactive protein levels were shown to be inversely
related to that of serum vitamin C levels, and supplementation
of vitamin C appeared to cause C-reactive protein levels to
decrease.

Benefits at low vs high doses
In Fowler et al, 2014, the patients who received the high-dose
ascorbic acid (200mg/kg) saw a faster rate of improvement in
terms of decreasing need for exogenous vasopressors and
decreased need for mechanical ventilation when compared to
patients who were given low-dose ascorbic acid (50mg/kg) or
placebo.

Cost of delaying new treatments
Due to the fact that the treatment components themselves are
relatively low cost, and the fact that thiamine and
hydrocortisone, as well as ascorbic acid in smaller doses, are
already often administered to critically-ill patients, and the
lack of evidence demonstrating serious adverse effects from
high-dose ascorbic acid, it seems reasonable in this case to
consider early implementation of this adjunct sepsis
treatment. The major flaw in this discussion is that since this
treatment is not being widely used, the costs and patient
outcomes were theoretical and based on an observational
study with a small sample size. More specific cost estimates
for the treatment as well as for training of staff could be
useful to aid in decision-making (Blythe, Cook, & Graves,
2018).

Discussion
Due to the large incidence and society cost of sepsis and its
sequelae, this has long been a major area of research. Several
novel sepsis treatments have appeared promising and failed to
produce meaningful results at the clinical trial level. Although
the seemingly-dramatic outcomes have been met with
skepticism by many, the current literature suggests that ascorbic
acid may be the most promising new treatment for sepsis that
clinicians have seen in a very long time. Its mechanism of
action in the body serves many roles that are not only vital to
the healthy individual, but physiologically suffering in cases of
sepsis. As previously mentioned, there are several currently
active clinical trials studying the use of intravenous ascorbic
acid in treating patients with sepsis. Within the next few years,
antioxidant therapy may become a viable treatment adjunct for
patients with severe sepsis. At a minimum, if it shows enough
benefit in early trials, the relatively low cost as well as lack of
risk of adverse effects may allow it to be implemented as part of
a sepsis protocol. In addition to larger sample sizes and blind,
placebo-controlled trials, a specific dosing recommendation
would need to be established, as well as at what point ascorbic
acid would be administered during the timeline of the sepsis
protocol.

Applicability to Clinical
Practice
As stated, there are several trials currently in various stages.
There are several areas that will need to be addressed before
widespread implementation can take place. While this research
currently applies to critical care as opposed to primary care,
significant benefit from use of high-dose ascorbic acid in
infectious disease could translate to research its use in less
severe illness. As more research becomes available, the use of
parenteral ascorbic acid could be a life-saving and cost-effective
treatment option for patients with severe sepsis.
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